Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine

References

• Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097–1105.
   PubMed Web of Science ®Google Scholar
• Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778–90.
   PubMed Web of Science ®Google Scholar
• Wang S-M, Liu -C-C. Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine. Expert Rev Anti Infect Ther. 2014;12(4):447–456.
   PubMed Web of Science ®Google Scholar
• Bessaud M, Razafindratsimandresy R, Nougairede A, et al. Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. Plos One. 2014;9(3):e90624.
   PubMed Web of Science ®Google Scholar
• Kung YA, Hung CT, Liu YC, et al. Update on the development of enterovirus 71 vaccines. Expert Opin Biol Ther. 2014;14(10):1455–1464.
   PubMed Web of Science ®Google Scholar
• Chong P, Liu -C-C, Chow Y-H, et al. Review of enterovirus 71 vaccines. Clin Infect Dis. 2015;60(5):797–803.
   PubMed Web of Science ®Google Scholar
• McMinn PC. Enterovirus vaccines for an emerging cause of brain-stem encephalitis. N Engl J Med. 2014;370(9):792–794.
   PubMed Web of Science ®Google Scholar
• Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308–18.
   PubMed Web of Science ®Google Scholar
• Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129(3):304–309.
   PubMed Web of Science ®Google Scholar
• A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD). WHO in the Western Pacific; 2011; [ cited 2016 Feb 22]. Available from: http://www.wpro.who.int/publications/docs/guidancefortheclinicalmanagementofhfmd.pdf
   Google Scholar
• Yip CC, Lau SK, Woo PC, et al. Human enterovirus 71 epidemics: what’s next? Emerg Health Threats J. 2013;6(19780):19780.
   PubMedGoogle Scholar
• Chong P, Hsieh S-Y, Liu -C-C, et al. Production of EV71 vaccine candidates. Hum Vaccin Immunother. 2012;8(12):1775–1783.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Meng F-Y, Li J-X, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024-32.
   PubMed Web of Science ®Google Scholar
• Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–28.
   PubMed Web of Science ®Google Scholar
• Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–37.
   PubMed Web of Science ®Google Scholar
• Chou AH, Liu CC, Chang JY, et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. Plos One. 2013;8(11):e79783.
   PubMed Web of Science ®Google Scholar
• Mao Q, Cheng T, Zhu F, et al. The cross-neutralizing activity of enterovirus 71 subgenotype C4 vaccines in healthy Chinese infants and children. Plos One. 2013;8(11):e79599.
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Yao X, et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother. 2014;10(2):360–367.
   PubMed Web of Science ®Google Scholar
• Bian L, Wang Y, Yao X, et al. Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide. Expert Rev Anti Infect Ther. 2015;13(9):1061–1071.
   PubMed Web of Science ®Google Scholar
• Wu Y, Yeo A, Phoon MC, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis IJID. 2010;14(12):e1076–81.
   PubMed Web of Science ®Google Scholar
• Lu QB, Zhang XA, Wo Y, et al. Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009-2011. Plos One. 2012;7(12):e52073.
   PubMed Web of Science ®Google Scholar
• Mirand A, Henquell C, Archimbaud C, et al. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infect. 2012;18(5):E110–8.
   PubMed Web of Science ®Google Scholar
• Lin T-Y, Kao H-T, Hsieh S-H, et al. Neonatal enterovirus infections: emphasis on risk factors of severe and fatal infections. Pediatr Infect Dis J. 2003;22(10):889–894.
   PubMed Web of Science ®Google Scholar
• Liu JN, Wang W, Duo JY, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28(46):7444–7451.
   PubMed Web of Science ®Google Scholar
• Chou AH, Liu CC, Chang JY, et al. Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol. 2012;2012:831282.
   PubMed Web of Science ®Google Scholar
• Tung WS, Bakar SA, Sekawi Z, et al. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007;5:6.
   PubMedGoogle Scholar
• Chen HF, Chang MH, Chiang BL, et al. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine. 2006;24(15):2944–2951.
   PubMed Web of Science ®Google Scholar
• Yee PT, Poh CL. Development of novel vaccines against enterovirus-71. Viruses. 2016;8(1). doi:10.3390/v8010001.
   Web of Science ®Google Scholar
• Lin SY, Chiu HY, Chiang BL, et al. Development of EV71 virus-like particle purification processes. Vaccine. 2015;33(44):5966–5973.
   PubMed Web of Science ®Google Scholar
• Chung Y-C, Ho M-S, Wu J-C, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26(15):1855–1862.
   PubMed Web of Science ®Google Scholar
• Chung C-Y, Chen C-Y, Lin S-Y, et al. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine. 2010;28(43):6951–6957.
   PubMed Web of Science ®Google Scholar
• Zhang C, Ku Z, Liu Q, et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33(20):2335–2341.
   PubMed Web of Science ®Google Scholar
• Lin SY, Yeh CT, Li WH, et al. Enhanced enterovirus 71 virus-like particle yield from a new baculovirus design. Biotechnol Bioeng. 2015;112(10):2005–2015.
   PubMed Web of Science ®Google Scholar
• Tsou YL, Lin YW, Shao HY, et al. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease. PLoS Negl Trop Dis. 2015;9(4):e0003692.
   PubMed Web of Science ®Google Scholar
• Dong C, Liu L, Zhao H, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011;29(37):6269–6275.
   PubMed Web of Science ®Google Scholar
• Bek EJ, Hussain KM, Phuektes P, et al. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine. 2011;29(29–30):4829–4838.
   PubMed Web of Science ®Google Scholar
• Li J-X, Mao Q-Y, Liang Z-L, et al. Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials. Expert Rev Vaccines. 2014;13(5):609-18.
   PubMed Web of Science ®Google Scholar
• Cai Y, Ku Z, Liu Q, et al. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine. 2014;32(21):2406–2412.
   PubMed Web of Science ®Google Scholar
• Lin C-W, Liu -C-C, Lu T-C, et al. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. Biomed Res Int. 2014;2014:1–8.
   Google Scholar
• Ku Z, Liu Q, Ye X, et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014;32(34):4296–4303.
   PubMed Web of Science ®Google Scholar
• Cheng A, Fung C-P, Liu -C-C, et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine. 2013;31(20):2471–2476.
   PubMed Web of Science ®Google Scholar
• Li Y-P, Liang Z-L, Gao Q, et al. Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine. 2012;30(22):3295–3303.
   PubMed Web of Science ®Google Scholar
• Li Y-P, Liang Z-L, Xia J-L, et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, double-blind, placebo-controlled Trial. J Infect Dis. 2014;209(1):46–55.
   PubMed Web of Science ®Google Scholar
• Meng F-Y, Li J-X, Li X-L, et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother. 2012;8(5):668–674.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Wang JZ, Li XL, et al. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in Chinese healthy children and infants. Pediatr Infect Dis J. 2012;31(11):1158–1165.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Liang Z-L, Li X-L, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013;381(9871):1037–1045.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang Y, Wang J, et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. Plos One. 2013;8(1):e54451.
   PubMed Web of Science ®Google Scholar
• Liang Z, Mao Q, Gao Q, et al. Establishing China’s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine. 2011;29(52):9668–9674.
   PubMed Web of Science ®Google Scholar
• Liu L, Mo Z, Liang Z, et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations. BMC medicine. 2015;13:226.
   PubMed Web of Science ®Google Scholar
• Li J-X, Song Y-F, Wang L, et al. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines. 2016;15(1):129–137.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu Z, Yang W, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7:94.
   PubMed Web of Science ®Google Scholar
• China Center for Disease Control and Prevention. [ cited 2016 Feb 22]. Available from: http://www.nhfpc.gov.cn/zhuzhan/yqxx/lists.shtml
   Google Scholar
• Gan Z-K, Jin H, Li J-X, et al. Disease burden of enterovirus 71 in rural central China: a community-based survey. Hum Vaccin Immunother. 2015;11(10):2400–2405.
   PubMed Web of Science ®Google Scholar
• Chia M-Y, Chiang P-S, Chung W-Y, et al. Epidemiology of enterovirus 71 infections in Taiwan. Pediatr Neonatol. 2014;55(4):243–249.
   PubMed Web of Science ®Google Scholar
• Jin P, Li J, Zhang X, et al. Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months. Hum Vaccin Immunother. 2016 Jan 11;12(4):916–921. doi:10.1080/21645515.2015.1118595
   PubMed Web of Science ®Google Scholar
• World Health Organization. Report on the WHO collaborative study to establish the 1st International Standard for anti-EV71 serum (Human); 2015. [ cited 2016 Feb 22]. Available from: http://www.who.int/biologicals/WHO_ECBS/en/
   Google Scholar
• Wu JT, Jit M, Zheng Y, et al. Routine pediatric enterovirus 71 vaccination in China: a cost-effectiveness analysis. PLoS Med. 2016;13(3):e1001975.
   PubMed Web of Science ®Google Scholar
• Crawford NW, Graham SM. EV71 vaccine: protection from a previously neglected disease. Lancet. 2013;381(9882):1968–1970.
   PubMed Web of Science ®Google Scholar
• Mao QY, Wang Y, Bian L, et al. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15(5):599–606.
   PubMed Web of Science ®Google Scholar
• Ma E, Fung C, Yip SH, et al. Estimation of the basic reproduction number of enterovirus 71 and coxsackievirus A16 in hand, foot, and mouth disease outbreaks. Pediatr Infect Dis J. 2011;30(8):675–679.
   PubMed Web of Science ®Google Scholar
• Li L, Yin H, An Z, et al. Considerations for developing an immunization strategy with enterovirus 71 vaccine. Vaccine. 2015;33(9):1107–1112.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The Immunological basis for immunization Series—module 6: poliomyelitis; 1993; [ cited 2016 Feb 22]. Available from: http://www.who.int/immunization/documents/WHO_EPI_GEN_93.16/en/
   Google Scholar
• Shenyu W, Jingxin L, Zhenglun ZL, et al. A booster dose of an inactivated enterovirus 71 vaccine in Chinese young children: a randomized, double-blind, placebo-controlled clinical trial. J Infect Dis. 2014;210(7):1073-82.
   PubMed Web of Science ®Google Scholar
• Lu S. EV71 vaccines: a milestone in the history of global vaccine development. Emerg Microbes Infect. 2014;3(4):e27.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Liang ZL, Meng FY, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. Plos One. 2012;7(5):e37206.
   PubMed Web of Science ®Google Scholar
• Liang ZL, Mao QY, Wang YP, et al. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother. 2013;9(8):1701–1705.
   PubMed Web of Science ®Google Scholar
• Lee MS, Tseng FC, Wang JR, et al. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis. 2012;6(8):e1737.
   PubMed Web of Science ®Google Scholar